We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+60.76%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$323M
AUM Growth
+$81M
Cap. Flow
+$51.5M
Cap. Flow %
15.94%
Top 10 Hldgs %
43.73%
Holding
97
New
25
Increased
29
Reduced
18
Closed
15

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$15M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$10.5M
3
KRYS icon
Krystal Biotech
KRYS
+$8.67M
4
BIIB icon
Biogen
BIIB
+$4.63M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$4.59M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$7.2M
2
NUVL
Nuvalent
NUVL
+$6.29M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.11M
4
PHVS icon
Pharvaris
PHVS
+$3.48M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$2.94M

Sector Composition

Rank Sector Weight
1 Healthcare 91.53%
2 Consumer Staples 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLYM
51
Climb Bio
CLYM
$704M
$1.38M 0.43%
494,089
+8,134
+2% +$24.7K
ANNX icon
52
Annexon
ANNX
$814M
$1.37M 0.42%
+389,911
New +$1.7M
ZURA icon
53
Zura Bio
ZURA
$526M
$1.31M 0.41%
+160,000
New +$1.29M
RETA
54
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$1.27M 0.39%
+12,500
New +$1.18M
ALKS icon
55
Alkermes
ALKS
$8.47B
$1.25M 0.39%
+40,000
New +$1.21M
VYGR icon
56
Voyager Therapeutics
VYGR
$184M
$1.15M 0.35%
+100,000
New +$1.03M
VRDN icon
57
Viridian Therapeutics
VRDN
$2.15B
$1.07M 0.33%
45,000
+8,619
+24% +$221K
RZLT icon
58
Rezolute
RZLT
$474M
$989K 0.31%
+499,544
New +$1.03M
KPTI icon
59
Karyopharm Therapeutics
KPTI
$161M
$929K 0.29%
34,599
-68,163
-66% -$2.94M
ALLK
60
DELISTED
Allakos
ALLK
$872K 0.27%
200,000
-11,010
-5% -$49.5K
BMRN icon
61
BioMarin Pharmaceuticals
BMRN
$12B
$867K 0.27%
+10,000
New +$941K
BBIO icon
62
BridgeBio Pharma
BBIO
$16.8B
$860K 0.27%
50,000
+10,000
+25% +$150K
PNT
63
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$849K 0.26%
93,700
-104,777
-53% -$924K
VTYX
64
DELISTED
Ventyx Biosciences
VTYX
$820K 0.25%
25,000
-45,000
-64% -$1.55M
PTGX icon
65
Protagonist Therapeutics
PTGX
$8.8B
$691K 0.21%
25,000
-80,486
-76% -$2.01M
JSPR icon
66
Jasper Therapeutics
JSPR
$21.1M
$685K 0.21%
50,000
– –
ALGS icon
67
Aligos Therapeutics
ALGS
$26.3M
$614K 0.19%
25,275
– –
BHVN icon
68
Biohaven
BHVN
$2.07B
$478K 0.15%
+20,000
New +$344K
SNDX icon
69
Syndax Pharmaceuticals
SNDX
$1.74B
$419K 0.13%
+20,000
New +$416K
CGEN icon
70
Compugen
CGEN
$214M
$376K 0.12%
330,188
– –
IMTX icon
71
Immatics
IMTX
$1.19B
$354K 0.11%
30,715
-251,717
-89% -$2.35M
CLDX icon
72
Celldex Therapeutics
CLDX
$2.79B
$339K 0.11%
10,000
-74,651
-88% -$2.52M
KYNB
73
CALL
Kyntra Bio
KYNB
$28.2M
$271K 0.08%
+4,000
New +$1.65M
CLNN icon
74
Clene
CLNN
$63.8M
$220K 0.07%
+12,500
New +$244K
GLUE icon
75
Monte Rosa Therapeutics
GLUE
$1.86B
$213K 0.07%
31,156
– –
1 2
3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
EWA
Evolution Wealth Advisors Aventura, Florida $981M AUM 21.2% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return

Silverarc Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Silverarc Capital Management held 97 positions worth $323M, up 33% from $242M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Silverarc Capital Management deployed $51.5M of net new capital in Q2 2023, opening 25 new positions and adding to 29 existing holdings. Its largest new stake was Mirati Therapeutics, Inc. Common Stock: 91,213 shares worth $3.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Nuvalent, an estimated $6.29M trimmed.

  • Silverarc Capital Management's largest Q2 2023 buy was Mirati Therapeutics, Inc. Common Stock: 91,213 shares worth $3.3M.
  • Silverarc Capital Management added most to Immunogen Inc in Q2 2023, an estimated $15M increase.
  • Silverarc Capital Management's biggest Q2 2023 reduction was Nuvalent, cutting an estimated $6.29M.
  • Silverarc Capital Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $7.2M.
  • Silverarc Capital Management's ten largest holdings make up 44% of its $323M portfolio in Q2 2023.
  • Silverarc Capital Management opened 25 new positions and closed 15 in Q2 2023.
  • Silverarc Capital Management's portfolio value rose 33% quarter-over-quarter to $323M.

Based on Silverarc Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.